Achmea Investment Management B.V. reduced its holdings in Celgene Co. (NASDAQ:CELG) by 55.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,966 shares of the biopharmaceutical company’s stock after selling 30,316 shares during the period. Achmea Investment Management B.V.’s holdings in Celgene were worth $3,111,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of CELG. Neuberger Berman Group LLC boosted its stake in shares of Celgene by 4.0% during the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock worth $229,553,000 after purchasing an additional 71,729 shares during the period. Grisanti Capital Management LLC purchased a new position in shares of Celgene during the 2nd quarter worth about $3,616,000. Lincoln Capital Corp boosted its stake in shares of Celgene by 0.6% during the 2nd quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock worth $3,971,000 after purchasing an additional 185 shares during the period. RiverPoint Capital Management LLC boosted its stake in shares of Celgene by 3.1% during the 2nd quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock worth $15,799,000 after purchasing an additional 3,680 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in shares of Celgene by 9.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock worth $83,344,000 after purchasing an additional 54,210 shares during the period. 80.16% of the stock is owned by institutional investors and hedge funds.

CELG has been the subject of a number of recent analyst reports. Vetr cut shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $146.88 price target for the company. in a research note on Tuesday, August 29th. Cantor Fitzgerald restated a “buy” rating on shares of Celgene in a report on Monday, August 28th. Robert W. Baird restated a “buy” rating and issued a $162.00 price target on shares of Celgene in a report on Thursday, September 21st. Jefferies Group restated a “buy” rating and issued a $160.00 price target on shares of Celgene in a report on Friday, September 15th. Finally, Mizuho boosted their price target on shares of Celgene from $134.00 to $158.00 and gave the company a “buy” rating in a report on Friday, September 15th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company’s stock. Celgene has an average rating of “Buy” and an average target price of $136.21.

In other Celgene news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.95% of the stock is currently owned by insiders.

Shares of Celgene Co. (CELG) opened at $109.41 on Friday. The firm has a market cap of $85,219.19, a P/E ratio of 16.91, a price-to-earnings-growth ratio of 0.83 and a beta of 1.78. Celgene Co. has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.

Celgene (NASDAQ:CELG) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. Celgene’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.58 EPS. equities analysts expect that Celgene Co. will post 6.68 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Achmea Investment Management B.V. Sells 30,316 Shares of Celgene Co. (CELG)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/achmea-investment-management-b-v-sells-30316-shares-of-celgene-co-celg/1767267.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.